

FOR IMMEDIATE RELEASE

Sun Pharma receives "will-not-sue" covenant on generic Effexor XR ® ANDA

Mumbai, October 16, 2007: Sun Pharmaceutical Industries Ltd. announced receipt of a Covenant Not to Sue from Wyeth over Sun Pharma's Abbreviated New Drug Application (ANDA) for generic venlafaxine extended release tablets with multiple para IV certifications.

This ANDA for generic venlafaxine extended release tablets, AB-rated equivalent of Wyeth's Effexor XR® Capsules, includes three strengths: 37.5 mg, 75 mg and 150 mg and is based on innovative technology for extended release tablets. These strengths of Effexor XR® Capsules have annual sales of approximately USD 2.6 billion in the US.

As per the Covenant, Wyeth covenants not to sue Sun under any claims of US Patent Nos. 6,274,171, 6,4013,120 and 6,419,958.

Venlafaxine is an antidepressant of the serotonin-norepinephrine reuptake inhibitor (SNRI) class.

Effexor XR [®] is a registered trademark of Wyeth Pharmaceuticals Inc.

About Sun Pharma

Established in 1983, listed since 1994 and headquartered in India, Sun Pharma (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715) is an international, integrated, speciality pharmaceutical company. It manufactures and markets a large basket of pharmaceutical formulations as branded generics as well as generics in India, US and several other markets across the world. In India, the company is a leader in niche therapy areas of psychiatry, neurology, cardiology, diabetology, gastroenterology, and orthopedics. The company has strong skills in product development, process chemistry, and manufacturing of complex API, as well as dosage forms. More information about the company can be found at www.sunpharma.com.

Contacts

| Uday Baldota | | Mira Desai | |
|--------------|----------------------------|------------|---------------------------|
| Tel | +91 22 6645 5645, Xtn 605 | Tel | +91 22 6645 5645, Xtn 606 |
| Tel Direct | +91 22 66455605 | Tel Direct | +91 22 66455606 |
| Mobile | +91 98670 10529 | Mobile | +91 98219 23797 |
| E mail | uday.baldota@sunpharma.com | E mail | miradesai@sunpharma.com |